Home | Publications | Drug Delivery place holder
place holder place holder

Drug Delivery

Beyond the Blockbuster Drug

Strategies for nichebuster drugs, targeted therapies and personalized medicine.

Publication Date   February 2005
Publisher   Business Insights
Product Type   Report
Pages   132
ISBN Number   not applicable
Product Code   RBI079
Ask a question about this product?

Price £1,495.00

approximately: $2,640 | €1,896

Summary


The blockbuster model now delivers just 5% return on investment and only one in six new drug prospects will deliver returns above their cost of capital, as a result competitive pressures and falling R&D productivity will instigate a new pharmaceutical model that replaces the unsustainable blockbuster model; personalized medicine and the "nichebuster". This report, Beyond the Blockbuster Drug: Strategies for nichebuster drugs, targeted therapies and personalized medicine, examines targeted therapies and targeted drug delivery strategies as alternative investment options for pharmaceutical companies, in the face of declining returns and slow growth in the blockbuster market. This report's strategic insight is also supported by in-depth interviews with thought leaders from the pharmaceutical industry, providing you with their insight into how tomorrow's pharmaceutical business model will develop. This report analyzes the niche pharmaceutical sectors with the greatest potential for profit and future growth. Harness the technological advances in personalized medicine and be part of the "nichebuster" revolution set to drive market growth and produce the market leading drugs of tomorrow.

Content


  • Executive Summary
    • The Blockbuster: An Unsustainable Model
    • Industry At A Crossroads
    • Beyond The Blockbuster: Personalized Medicine
    • Targeted Medicine: Oncology
    • New Drug Technologies: Discovery And Delivery
    • Drug Development: Outsourcing And Partnering
    • Case Study: Roche
    • Case Study: Novartis
    • Creating Tomorrow's Winning Company
  • Chapter 1 The Blockbuster: An Unsustainable Model
    • Summary
    • Introduction
    • The Rise And Fall Of The Blockbuster Phenomenon
    • The Blockbuster Phenomenon
    • When Blockbusters Come Off Patent
    • Implications For The Future Of The Industry
  • Chapter 2 The Industry At A Crossroads
    • Summary
    • The Failure Of R&d
    • The R&d Performance Gap
    • The Failure Of The 'Mega-Merger'
    • Conclusion
  • Chapter 3 Beyond The Blockbuster: Personalized Medicine
    • Summary
    • Where Next?
    • Personalized Medicine
    • Gene-Based Therapies Reach The Market By 2010
    • The Race For New Therapies
    • Conclusion
  • Chapter 4 Targeted Medicine: Oncology
    • Summary
    • Introduction
    • A Promising Therapeutic Field
    • Gleevec
    • Therapeutic Focus On Cancer
    • Drug Discovery Deals
    • Molecularly Targeted Therapies
    • Herceptin
    • Promising Treatments For Breast Cancer
    • Advances In Treatment For Colorectal Cancer
    • Prostate Cancer
    • Conclusion
  • Chapter 5 Targeted Drug Delivery
    • Summary
    • New Drug Technologies
    • Customized Medicine
    • A Future Of Unseen Opportunity
    • Advances In Science
    • Targeted Drug Delivery
    • Oral Delivery Of Macromolecules
    • Enhanced Bioavailability / Efflux Inhibitors
    • Scf Technologies
    • Inhibiting P-Gp Action
    • Injectable, Biodegradable Depot Drug Delivery
    • Parenteral Drug Delivery
    • Pegylation To Deliver Protein And Cancer Drugs
    • Conclusion
  • Chapter 6 Drug Development: Outsourcing And Partnering
    • Summary
    • Introduction
    • Why Outsource?
    • The Changing Cro Model
    • Biotechs Are Reshaping Drug Development
    • Moving From Vendor To Strategic Partner
    • Realizing Strategic Value
    • The Ideal Cro Model For The New Outsourcing Paradigm
    • Models For Outsourcing
    • Do-It-Yourself
    • Architect
    • Integrated Design And Build
    • Risk-Sharing
    • Conclusion
  • Chapter 7 Case Study: Roche
    • Summary
    • Banking On 'Nichebusters'
    • A Radically Transformed Roche Portfolio
    • Diagnostics: An Essential Precursor For Targeted Medicines
    • R&d Partnerships For Faster Growth
    • Conclusion
  • Chapter 8 Case Study: Novartis
    • Summary
    • Targeted Medicine
    • Breadth Vs Depth?
    • Novartis Portfolio
    • Ptk787 (Zx 222584)
    • Icl670
    • Gimatecan
    • Femara
    • Conclusion
    • Beyond Targeted Medicine
  • Chapter 9 Creating Tomorrow's Winning Company
    • Summary
    • Prisoners Of Roi
    • Adding A Dimension To The Matrix
    • Pharmaceutical Companies As Service Providers
    • Boom Times Knocking At The Door... But Not Without Change
    • Alliances Fuel Innovation
    • Growing A Product To Its Maximum Sales
    • Medicines For 'My' Body
    • A Broader View Of The Competition
    • Far-Reaching Psychological And Structural Transformation
    • Conclusion
    • Index
  • List Of Figures
    • Figure 1.1: From Therapy To Health Maintenance Busters
    • Figure 2.2: Emergence Of An Elite Group Of R&d Spenders
    • Figure 2.3: Ten Year Evolution Of A Drug's Development Cost
    • Figure 2.4: Declining R&d Success*
    • Figure 2.5: Drug Candidates Of Major R&d-Driven Pharma Companies
    • Figure 2.6: Performance Gap In R&d
    • Figure 2.7: Breakdown Of Projects By Clinical Phase And Source Of Drug
    • Figure 2.8: No Economies Of Scale In Pharmaceutical R&d
    • Figure 2.9: Shareholder Returns Of Merged And Non-Merged Companies
    • Figure 2.10: The Need For Alliances And Partnering
    • Figure 3.11: Genomic Research Based Products Reach The Market Before 2010
    • Figure 3.12: Genetically Manufactured Substances In The Pipeline
    • Figure 4.13: Therapeutic Focus Of Clinical Pipeline Activity
    • Figure 4.14: Global Oncology Players, 2002
    • Figure 4.15: Deals By Therapeutic Focus (Sept '02 T0 Mar '04)
    • Figure 4.16: Therapeutic Focus By Company (Sept '02 To Mar '04)
    • Figure 4.17: Development Of The Global Oncology Market 2001-2008*
    • Figure 4.18: Breast Cancer Market Opportunities
    • Figure 6.19: Today's R&d Environment
    • Figure 6.20: The Future R&d Environment
    • Figure 7.21: Leading Products In The Roche Portfolio, 2003
    • Figure 7.22: The Roche Business Model: Innovation And Diagnostics
    • Figure 8.23: Novartis, Sales By Type Of Business Activity ($M), 2003
    • Figure 8.24: External Sources Contribute To Novartis Product Growth
    • Figure 9.25: Drug Discovery Holds Immense Possibilities
    • Figure 9.26: Reshaping The 'Traditional' Healthcare Model
    • Figure 9.27: The Integrated Virtual Megapharma-Biotech Company
  • List Of Tables
    • Table 3.1: Drug Candidates In Early Stage Clinical Development, 2002-2003
    • Table 4.2: Cancer Pathologies (Selected) In The Us
    • Table 5.3: Novel Drug Technologies
    • Table 7.4: Roche: Early Stage Development Alliances
    • Table 8.5: Estimated Product Launch Timetable For Novartis Drug Pipeline